Home > Insider Trading > Filing (0001209191-15-085975)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1411158	Anacor Pharmaceuticals Inc.	ANAC	Pharmaceutical Preparations (2834)	251854385

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1571819	Lee Zane	C/O Anacor Pharmaceuticals, Inc. 1020 East Meadow Circle Palo Alto CA 94303	Svp And Chief Medical Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2015-12-15	14,000	$5.59	42,747	No	4	M	Direct
Common Stock	Disposition	2015-12-15	1,574	$112.06	41,173	No	4	S	Direct
Common Stock	Disposition	2015-12-15	9,430	$113.14	31,743	No	4	S	Direct
Common Stock	Disposition	2015-12-15	2,896	$113.79	28,847	No	4	S	Direct
Common Stock	Disposition	2015-12-15	100	$114.99	28,747	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (right to buy)	Disposition	2015-12-15	14,000	$0.00	14,000	$5.59

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
27,661		2022-03-13	No	4	M	Direct

Footnotes

Includes shares purchased in 2015 pursuant to the Issuer's ESPP.
This sale was effected pursuant to a pre-existing Rule 10b5-1 trading plan adopted by the reporting person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.55 to $112.54, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.56 to $113.55, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $113.56 to $114.055, inclusive.
The award is subject to a four-year vesting period, with 25% of the shares subject to the award vesting in an initial annual installment following the Vesting Commencement Date and 1/48th of the shares subject to the award vesting each month thereafter. The Vesting Commencement Date was January 1, 2012.